An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Nipocalimab (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms Vibrance-MG
- Sponsors Janssen Research & Development
Most Recent Events
- 10 Apr 2025 Planned primary completion date changed from 19 Mar 2025 to 30 Jun 2026.
- 11 Mar 2025 Planned End Date changed from 30 Dec 2025 to 31 Dec 2026.
- 16 Oct 2024 Results presented in a Johnson & Johnson Media Release.